Article
Clinical Neurology
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S. Bell Lynum, Sanjeda R. Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R. Saklad
Summary: Aripiprazole 2-month ready-to-use 960 mg and Aripiprazole lauroxil 1064 mg are both long-acting injectable formulations used for the treatment of schizophrenia. Comparing the drug concentrations, both formulations maintain therapeutic levels over the 2-month dosing interval.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Medical Laboratory Technology
Minami Tasaki, Norio Yasui-Furukori, Kazuyoshi Kubo, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Yoshimasa Inoue, Kazutaka Shimoda
Summary: The study found that lower prolactin levels are associated with higher plasma drug concentrations in male and female patients with schizophrenia treated with aripiprazole.
THERAPEUTIC DRUG MONITORING
(2021)
Review
Psychiatry
Yikang Zhu, Caidi Zhang, Spyridon Siafis, Kaiming Zhuo, Dianming Zhu, Hui Wu, Dengtang Liu, Kaida Jiang, Jijun Wang, Stefan Leucht, Chunbo Li
Summary: The study included 130 RCTs with 25,610 participants and found that newer and older antipsychotics all increase prolactin levels significantly. Sensitivity analyses showed that removing studies with baseline imbalance or high risk of bias did not impact the results. In contrast to previous findings, clozapine and zotepine were no longer associated with decreased prolactin levels compared to placebo, and risperidone's ranking was found to have more implications supported by CINeMA.
SCHIZOPHRENIA RESEARCH
(2021)
Article
Clinical Neurology
Marcos Gomez-Revuelta, Jose Maria Pelayo-Teran, Javier Vazquez-Bourgon, Victor Ortiz-Garcia de la Foz, Jacqueline Mayoral-van Son, Rosa Ayesa-Arriola, Benedicto Crespo-Facorro
Summary: This study compared the effectiveness of aripiprazole and risperidone in the acute-phase treatment of FEP and found no differences in treatment discontinuation rates and mean time until discontinuation between the two drugs. However, risperidone showed better performance in terms of clinical efficacy, but patients on risperidone were more likely to experience sex-related adverse events.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Psychiatry
Renata Alisauskiene, Erik Johnsen, Rolf Gjestad, Rune A. Kroken, Eirik Kjelby, Igne Sinkeviciute, Farivar Fathian, Inge Joa, Solveig Klaebo Reitan, Maria Rettenbacher, Else-Marie Loberg
Summary: This study investigated the influence of drug use on the effectiveness of antipsychotic medication in patients with schizophrenia spectrum disorders (SSD). The results showed no significant differences in effectiveness among the three studied antipsychotics, regardless of drug use. However, older patients in the drug use group showed greater reduction in PANSS positive subscale score during treatment with amisulpride. Therefore, amisulpride may be a suitable choice for older patients with drug use.
GENERAL HOSPITAL PSYCHIATRY
(2023)
Article
Psychiatry
Wang Zhenhua, Chen Haizhi, Li Jing, Fei Xiaocong, Li Jianhua, Liu Jianjun, Lei Lilei, Jin Haiying
Summary: Risperidone and amisulpride can cause hyperprolactinemia and macroprolactinemia, and detection of MPRL in the clinical setting is important as this phenomenon appears early in treatment (the second week) and continues, which can prevent unnecessary examination and treatment for asymptomatic patients with macroprolactinemia.
ASIA-PACIFIC PSYCHIATRY
(2022)
Article
Pharmacology & Pharmacy
Blanca Fernandez-Abascal, Maria Recio-Barbero, Margarita Saenz-Herrero, Rafael Segarra
Summary: This study presents the first six-case series of pregnant women with schizophrenia treated with aripiprazole long-acting antipsychotic formulations. The results showed that all patients remained psychopathologically stable through pregnancy and the postpartum period, with all infants remaining healthy without any congenital malformations or adverse effects. Further studies with a larger number of patients are needed to provide more safety data for the use of new antipsychotic formulations in pregnant women with mental illness.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2021)
Article
Clinical Neurology
Lucia Garrido-Sanchez, Marcos Gomez-Revuelta, Victor Ortiz-Garcia De la Foz, Jose Maria Pelayo-Teran, Maria Juncal-Ruiz, Miguel Ruiz-Veguilla, Jacqueline Mayoral-Van Son, Rosa Ayesa-Arriola, Javier Vazquez-Bourgon, Benedicto Crespo-Facorro
Summary: This study compared the short-term effectiveness of aripiprazole and risperidone in patients with first episode psychosis (FEP). The results showed no statistically significant differences in treatment discontinuation rates and time to discontinuation between the two drugs. However, aripiprazole required higher dosage and extended time to achieve clinical response.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Le Xiao, Qian Zhao, An-ning Li, Jushui Sun, Bin Wu, Lina Wang, Honggeng Zhang, Ruiling Zhang, Keqing Li, Xiaojin Xu, Tiebang Liu, Wenshun Zhang, Shiping Xie, Xiufeng Xu, Yunlong Tan, Kerang Zhang, Hongyan Zhang, Nianhong Guan, Mingji Xian, Motomichi Uki, Gang Wang
Summary: The study evaluated the efficacy and safety of aripiprazole once-monthly (AOM) compared to oral aripiprazole in treating acute schizophrenia. The results showed that AOM was non-inferior to oral aripiprazole in terms of efficacy and tolerability. These findings suggest that AOM could be a treatment option for patients experiencing an acute episode of schizophrenia.
PSYCHOPHARMACOLOGY
(2022)
Review
Oncology
Zheng Gao, Yin Xi, Hekai Shi, Jiyuan Ni, Wei Xu, Kaili Zhang
Summary: The use of antipsychotics is associated with an increased risk of breast cancer, with no significant difference between typical and atypical antipsychotics. High-dose exposure to antipsychotics also increases the likelihood of breast cancer development. Additionally, antipsychotic use is linked to higher mortality rates in breast cancer patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Psychiatry
Xuebing Liu, Xianzhi Sun, Lu Li, Kuan Zeng, Yi Li, Yujun Gao, Jun Ma
Summary: This study found that compared with the group without co-prescribed aripiprazole, the group with co-prescribed aripiprazole had significantly higher levels of fasting blood glucose, blood uric acid, total cholesterol, triglyceride, and low-density lipoprotein cholesterol in long-term hospitalized chronic schizophrenia patients with co-morbid type 2 diabetes. However, there was no difference in prolactin levels. Co-prescribing aripiprazole had no impact on prolactin levels in patients with co-morbid type 2 diabetes.
FRONTIERS IN PSYCHIATRY
(2023)
Review
Pharmacology & Pharmacy
Adriana Stelmach, Katarzyna Guzek, Alicja Roznowska, Irena Najbar, Anna Sadakierska-Chudy
Summary: Second-generation antipsychotics, including aripiprazole, are commonly used for treating schizophrenia. Aripiprazole is a third-generation antipsychotic drug that acts on dopamine and serotonin receptors, with minimal side effects. However, some patients may have an inadequate response to aripiprazole treatment, and genetic polymorphisms, including CYP2D6, CYP3A4, CYP3A5, ABCB1, DRD2, and 5-HTRs, may influence the therapeutic effects and metabolic response to the drug. A pharmacogenetic approach may be beneficial in predicting drug response and improving the management of schizophrenia patients.
PHARMACOLOGICAL REPORTS
(2023)
Article
Multidisciplinary Sciences
Seoyoung Kim, Elena Younhye Ock, Jun Soo Kwon, Euitae Kim
Summary: This study investigated the relationship between aripiprazole and subjective well-being. The findings showed a significant negative correlation between the D2 receptor occupancy by aripiprazole and subjective well-being, while no correlation was found with clinical symptoms. This suggests that clinicians should find the lowest effective doses of aripiprazole for stable patients to improve their subjective experiences and clinical outcomes.
SCIENTIFIC REPORTS
(2022)
Article
Psychiatry
Falmata Baba Shettima, Musa Abba Wakil, Taiwo Lateef Sheikh, Mohammed Abdulaziz, Isa Bukar Rabbebe, Ibrahim Abdu Wakawa, Ogualili Placidus
Summary: The prevalence of sexual dysfunction is high among patients with schizophrenia spectrum disorders receiving antipsychotic medication. Independent correlates of sexual dysfunction include female gender, being unmarried, pseudoparkinsonism, prolactin levels, and severity of illness.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Paula Soria-Chacartegui, Gonzalo Villapalos-Garcia, Pablo Zubiaur, Francisco Abad-Santos, Dora Koller
Summary: Olanzapine, aripiprazole, and risperidone are widely used for schizophrenia treatment and can induce various adverse drug reactions. The metabolism and individual genetic polymorphisms of these drugs affect pharmacokinetics and drug responses, necessitating consideration of patient genotypes and potential drug interactions during treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Nadia Deflorin, Ulrike Ehlert, Rita T. Amiel Castro
Summary: Changes in the gut microbiome of infants have been associated with maternal psychological symptoms during pregnancy. This study found that maternal prenatal depressive symptoms are associated with lower diversity of the infant's microbiome, while maternal saliva cortisol levels are linked to increased diversity and changes in specific bacterial groups. Further research is needed to understand the implications of these microbiota alterations for child health.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Zheng Ma, Hui-Xia Zhou, Da-Chun Chen, Dong-Mei Wang, Xiang-Yang Zhang
Summary: The impaired glucose metabolism in drug-na & iuml;ve schizophrenia patients is strongly associated with suicidal behavior, suggesting that glucose metabolism abnormalities may be potential biomarkers of suicide in schizophrenia patients. Regular monitoring of glucose metabolism variables is essential for suicide prevention.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Katie M. Lavigne, Jiaxuan Deng, Delphine Raucher-Chene, Adele Hotte-Meunier, Chloe Voyer, Lisa Sarraf, Martin Lepage, Genevieve Sauve
Summary: Psychiatric disorders are characterized by cognitive deficits and cognitive biases, which are associated with specific symptoms. While cognitive biases are present across diagnoses, their severity varies.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Yong-Yu Yin, Jiao-Zhao Yan, Shi-Xin Lai, Qian-Qian Wei, Si-Rui Sun, Li-Ming Zhang, Yun-Feng Li
Summary: This study found that gamma oscillations are closely associated with depression and may serve as predictive biomarkers of depression. Chronic restraint stress and lipopolysaccharide induced significant depression-like behaviors in mice and reduced gamma oscillations in the medial prefrontal cortex. Administration of ketamine, scopolamine, or fluoxetine increased gamma oscillations and exhibited rapid-acting antidepressant effects.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Veronica Begni, Moira Marizzoni, Kerstin Camile Creutzberg, Diana Morena Silipo, Mariusz Papp, Annamaria Cattaneo, Marco Andrea Riva
Summary: Exposure to stressful experiences is a significant risk factor for mental disorders, and pharmacological interventions targeting stress-induced alterations can help restore brain function. Lurasidone, an antipsychotic drug, has been shown to normalize the impairments caused by stress exposure and could be a valuable treatment for stress-induced mental illnesses. However, the mechanisms underlying the therapeutic effects of lurasidone are not well understood. This study found that chronic lurasidone treatment counteracted some of the transcriptional changes induced by chronic mild stress exposure, providing new insights into the potential therapeutic effects of lurasidone.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Esther E. Palacios-Barrios, Kunal Patel, Jamie L. Hanson
Summary: This review examines the association between early life interpersonal stress (ELIS) and depression, as well as the underlying mechanisms. The research shows that ELIS affects how youth respond to social rewards, and similar impairments in social reward processing are observed in youth with depression. The authors propose a preliminary model that suggests neurobehavioral disruptions in social reward processing as a mediating factor in the connection between ELIS and depression.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Rui Li, Jiaming Tang, Yizhuo Wang, Ying Wang, Hua Yang, Hongen Wei
Summary: Restricted and repetitive behaviors (RRBs) are characteristic features of neuropsychiatric disorders. This study focused on repetitive self-grooming behavior and investigated the involvement of the Pax2 gene in its control. Through the use of Pax2 neuron-specific deletion mice, the study found that the deletion of Pax2 gene affects the expression of the Arc gene in the prefrontal cortex, leading to impaired synaptic plasticity and excitatory/inhibitory imbalance, thereby contributing to the occurrence of repetitive self-grooming behavior.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Sara Derosa, Paulina Misztak, Jessica Mingardi, Giulia Mazzini, Heidi Kaastrup Muller, Laura Musazzi
Summary: This study investigated the involvement of neurotrophic signaling pathways in stress vulnerability/resilience and fast antidepressant response/non-response to ketamine in a rat model of depression. The findings showed that stress and ketamine induced specific changes in these pathways in different brain areas and subcellular fractions.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Review
Clinical Neurology
Georgia F. Caruana, Sean P. Carruthers, Michael Berk, Susan L. Rossell, Tamsyn E. Van Rheenen
Summary: Cognitive impairment is related to both white matter macrostructure and microstructure in bipolar disorder patients. However, there is inconsistency in the results of the studies examining this relationship. Some studies have found an association between higher fractional anisotropy in white matter and better complex attention skills and executive functioning in bipolar disorder patients, while others have found no associations. Further research with increased statistical power and standardized methods is needed.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Review
Clinical Neurology
Alberto Galimberti, Martin Tik, Giovanni Pellegrino, Anna-Lisa Schuler
Summary: This study provides a systematic review and meta-analysis on the effectiveness of repetitive transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) for post-traumatic brain injury (TBI) symptoms. The results show that non-invasive brain stimulation techniques have a small overall effect on TBI sequelae, with significant effects observed for anxiety and headache. However, larger randomized controlled trials with longer follow-ups, optimized stimulation parameters, and standardized methodology are needed to establish the efficacy of these techniques in addressing TBI sequelae.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Amanda J. Sales, Pedro H. Gobira, Joa F. C. Pedrazzi, Joao R. Silveia, Elaine Del Bel, Felipe V. Gomes, Francisco S. Guimaraes
Summary: The study found that doxycycline can inhibit metalloproteinase in the brain and attenuate the rewarding effects and locomotor sensitization of drug abuse. This suggests that doxycycline could be repurposed for the treatment of substance use disorders.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Alejandro Borrego-Ruiz, Juan J. Borrego
Summary: There is substantial evidence that the development of the nervous system is related to the composition and functions of the gut microbiome. The communication between the central nervous system (CNS) and the gut microbiota is bidirectional, with various routes such as immune, endocrine, and neural circuits. Dysbiosis of the gut microbiota has been associated with neuropsychiatric diseases and psychological disorders. Fecal microbiota transplantation (FMT) therapy has shown a causal-effect relationship between the gut microbiota and behavioral features. Interventions based on prebiotics, probiotics, or synbiotics have demonstrated their influence on neurological disorders through the synthesis of neuroactive compounds and regulation of inflammatory and endocrine processes. Further research is needed to explore the impact of gut microbiota dysbiosis on psychiatric and psychological disorders and the potential therapeutic role of microbiota-based interventions.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Zhinan Li, Zhuang Kang, Xiaowei Xia, Leijun Li, Junyan Wu, Jiamin Dai, Tong Liu, Cai Chen, Yong Qiu, Ming Chen, Yanxi Liu, Ziyi Zhang, Zili Han, Zhengjia Dai, Qinling Wei
Summary: This study found that patients with schizophrenia showed lower levels of resilience and cognitive functions compared to healthy controls, as well as abnormal global properties and nodal metrics in brain networks. Furthermore, characteristic path length might moderate the relationship between resilience and working memory in these patients.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
David H. Adamowicz, Tsung-Chin Wu, Rebecca Daly, Michael R. Irwin, Dilip Jeste, Xin M. Tu, Lisa T. Eyler, Ellen E. Lee
Summary: This study aimed to explore the relationship between executive functioning and inflammatory biomarkers in people with schizophrenia. The results showed that systemic inflammation did not predict long-term declines in executive functioning. This suggests the need for further research to better understand the relationship and mechanisms between inflammation and cognition in schizophrenia.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Nina Walter, Julian Wenzel, Shalaila S. Haas, Letizia Squarcina, Carolina Bonivento, Anne Ruef, Dominic Dwyer, Theresa Lichtenstein, Oeznur Bastruek, Alexandra Stainton, Linda A. Antonucci, Paolo Brambilla, Stephen J. Wood, Rachel Upthegrove, Stefan Borgwardt, Rebekka Lencer, Eva Meisenzahl, Raimo K. R. Salokangas, Christos Pantelis, Alessandro Bertolino, Nikolaos Koutsouleris, Joseph Kambeitz, Lana Kambeitz-Ilankovic
Summary: Clinical and neuroimaging data can be used to predict the potential of cognitive training to improve social functioning in recent onset psychosis patients. The use of multivariate pattern analysis and support vector machine classifier allows for the prediction of social functioning improvement based on baseline cognitive data. The findings suggest that cognitive data can provide a robust individual estimate of future social functioning for patients with recent onset psychosis.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)